372156-99-5

Usage

Uses

Used in Pharmaceutical Production:
2,4-Dimethylpyridine-3-carboxylic acid N-oxide is used as a key intermediate in the synthesis of pharmaceuticals, contributing to the development of new drugs and medicines.
Used in Agrochemical Production:
2,4-DIMETHYLPYRIDINE-3-CARBOXYLIC ACID N-OXIDE is also utilized in the production of agrochemicals, serving as a building block for the creation of effective pesticides and other agricultural products.
Used in Organic Electronics:
2,4-Dimethylpyridine-3-carboxylic acid N-oxide is used as a component in the development of organic electronics, potentially enhancing the performance of electronic devices and contributing to the advancement of this field.
Used in Synthesis of New Materials:
As a versatile building block, 2,4-Dimethylpyridine-3-carboxylic acid N-oxide is used in the synthesis of new materials, expanding the range of compounds available for various industrial applications.
Used in Biological Research:
2,4-Dimethylpyridine-3-carboxylic acid N-oxide is used as a subject of biological research for its potential antibacterial and antifungal properties, which could lead to the discovery of new treatments and applications in the field of microbiology.

InChI:InChI=1/C8H9NO3/c1-5-3-4-9(12)6(2)7(5)8(10)11/h3-4H,1-2H3,(H,10,11)

Upstream product

• 55314-30-2 2,4-dimethylnicotinic acid 
• 405058-67-5 2,4-dimethyl-1-oxy-nicotinic acid ethyl ester 
• 37669-78-6 ethyl 2,4-dimethylnicotinate 

Downstream Products

• 370893-06-4 ancriviroc 
• 678975-03-6 4-({[1'-(2,4-dimethyl-1-oxy-pyridine-3-carbonyl)-4'-methyl-[1,4']bipiperidinyl-4-yl]-phenyl-amino}-methyl)-benzonitrile 
• 306293-41-4 Sch 350634 

Relevant academic research and scientific papers

Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication

A series of CCR5 antagonists were optimized for potent inhibition of R5 HIV-1 replication in peripheral blood mononuclear cells. Compounds that met acceptable ADME criteria, selectivity, human plasma protein binding, potency shift in the presence of α-glycoprotein were evaluated in rat and dog pharmacokinetics.

Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity

We previously reported the discovery of 4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-1′-[(2,4-dimethyl-3 -pyridinyl)carbonyl]-4′-methyl-1,4′-bipipefidine N-oxide 1 (SCH 351125) as an orally bioavailable human CCR5 antagonist for the treatment of HIV-1 infec

Discovery of 4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-1′-[(2,4-dimethyl- 3pyridinyl)carbonyl]-4′-methyl-1,4′bipiperidine N-oxide (SCH 351125): An orally bioavailable human CCR5 antagonist for the treatment of HIV infection

Structure - activity studies on piperidino-piperidine 3 led to the discovery of SCH 351125 (1), a selective CCR5 antagonist with potent activity against RANTES binding (Ki=2 nM), which possesses subnanomolar activity in blocking viral entry and